BACKGROUND: Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HCT). In mice, naive T cells (TN) cause more severe GVHD than memory T cells (TM). We hypothesized that selective depletion of TN from human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GVHD and provide sufficient numbers of hematopoietic stem cells and TM to permit hematopoietic engraftment and the transfer of pathogen-specific T cells from donor to recipient, respectively. METHODS: In a single-arm clinical trial, we transplanted 35 patients with high-risk leukemia with TN-depleted PBSC grafts following conditioning with total body irradiation, thiotepa, and fludarabine. GVHD prophylactic management was with tacrolimus immunosuppression alone. Subjects received CD34-selected PBSCs and a defined dose of TM purged of CD45RA+ TN. Primary and secondary objectives included engraftment, acute and chronic GVHD, and immune reconstitution. RESULTS: All recipients of TN-depleted PBSCs engrafted. The incidence of acute GVHD was not reduced; however, GVHD in these patients was universally corticosteroid responsive. Chronic GVHD was remarkably infrequent (9%; median follow-up 932 days) compared with historical rates of approximately 50% with T cell-replete grafts. TM in the graft resulted in rapid T cell recovery and transfer of protective virus-specific immunity. Excessive rates of infection or relapse did not occur and overall survival was 78% at 2 years. CONCLUSION: Depletion of TN from stem cell allografts reduces the incidence of chronic GVHD, while preserving the transfer of functional T cell memory. TRIAL REGISTRATION: ClinicalTrials.gov (NCT 00914940).
BACKGROUND:Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HCT). In mice, naive T cells (TN) cause more severe GVHD than memory T cells (TM). We hypothesized that selective depletion of TN from human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GVHD and provide sufficient numbers of hematopoietic stem cells and TM to permit hematopoietic engraftment and the transfer of pathogen-specific T cells from donor to recipient, respectively. METHODS: In a single-arm clinical trial, we transplanted 35 patients with high-risk leukemia with TN-depleted PBSC grafts following conditioning with total body irradiation, thiotepa, and fludarabine. GVHD prophylactic management was with tacrolimus immunosuppression alone. Subjects received CD34-selected PBSCs and a defined dose of TM purged of CD45RA+ TN. Primary and secondary objectives included engraftment, acute and chronic GVHD, and immune reconstitution. RESULTS: All recipients of TN-depleted PBSCs engrafted. The incidence of acute GVHD was not reduced; however, GVHD in these patients was universally corticosteroid responsive. Chronic GVHD was remarkably infrequent (9%; median follow-up 932 days) compared with historical rates of approximately 50% with T cell-replete grafts. TM in the graft resulted in rapid T cell recovery and transfer of protective virus-specific immunity. Excessive rates of infection or relapse did not occur and overall survival was 78% at 2 years. CONCLUSION: Depletion of TN from stem cell allografts reduces the incidence of chronic GVHD, while preserving the transfer of functional T cell memory. TRIAL REGISTRATION: ClinicalTrials.gov (NCT 00914940).
Authors: Juliet N Barker; Rachael E Hough; Jo-Anne H van Burik; Todd E DeFor; Margaret L MacMillan; Michele R O'Brien; John E Wagner Journal: Biol Blood Marrow Transplant Date: 2005-05 Impact factor: 5.742
Authors: Nabila Seddiki; Brigitte Santner-Nanan; Jeff Martinson; John Zaunders; Sarah Sasson; Alan Landay; Michael Solomon; Warwick Selby; Stephen I Alexander; Ralph Nanan; Anthony Kelleher; Barbara Fazekas de St Groth Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Sami B Kanaan; Hilary S Gammill; Whitney E Harrington; Stephen C De Rosa; Philip A Stevenson; Alexandra M Forsyth; Judy Allen; Emma Cousin; Koen van Besien; Colleen S Delaney; J Lee Nelson Journal: Oncoimmunology Date: 2017-03-31 Impact factor: 8.110
Authors: Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth Journal: Haematologica Date: 2016-06-27 Impact factor: 9.941
Authors: George B McDonald; Laura Tabellini; Barry E Storer; Paul J Martin; Richard L Lawler; Steven L Rosinski; H Gary Schoch; John A Hansen Journal: Biol Blood Marrow Transplant Date: 2017-05-03 Impact factor: 5.742
Authors: Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik Journal: J Immunol Date: 2017-12-06 Impact factor: 5.422